Just Healthcare

Just Healthcare

Share this post

Just Healthcare
Just Healthcare
Experimental Multiple Sclerosis Treatment Frexalimab Shows Impressive Results

Experimental Multiple Sclerosis Treatment Frexalimab Shows Impressive Results

Promising new drug significantly reduces MS disease activity, with minimal side effects.

Naveen Sankar S's avatar
Naveen Sankar S
Jun 14, 2025
∙ Paid
4

Share this post

Just Healthcare
Just Healthcare
Experimental Multiple Sclerosis Treatment Frexalimab Shows Impressive Results
1
Share
Generated image

Topline

An experimental multiple sclerosis (MS) drug, frexalimab, demonstrates near-complete suppression of disease activity over two years, showing remarkable effectiveness in clinical trials.

Study Details

Researchers investigated frexalimab, a second-generation anti-CD40 ligand monoclonal antibody, known for modulating both B-cell and T-cell activity w…

Keep reading with a 7-day free trial

Subscribe to Just Healthcare to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 Just Healthcare
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share